From Medscape Oncology

Coverage from the

Gastrointestinal Cancers Symposium (GICS) 2023

January 19 - 21, 2023; San Francisco, CA and Virtual/Online

January 19 - 21, 2023 San Francisco, CA and Virtual/Online

GICS 2023 SUNLIGHT: New Standard of Care in Refractory Metastatic CRC The SUNLIGHT trial results show that adding bevacizumab to trifluridine/tipiracil (Lonsurf) improves median overall and progression free survival without increasing the risk for serious adverse events.
Medscape Medical News, January 23, 2023
GICS 2023 Adding SBRT to Sorafenib Boosts Survival in Liver Cancer Adding stereotactic body radiation therapy (SBRT) to treatment with sorafenib improved overall survival and progression-free survival as well as quality of life.
Medscape Medical News, January 23, 2023

Conference News

GICS 2023 Liver Transplants for CRC Metastases: Coming Into Its Own?
Medscape Medical News, April 11, 2023
GICS 2023 Antibiotics OK With Immunotherapy for Biliary Tract Cancer
MDedge News, February 10, 2023
GICS 2023 Colorectal Cancer Treatment Outcomes in Older Adults
MDedge News, February 10, 2023
GICS 2023 Long-Course RT Better at Organ-Sparing in Rectal Cancer
MDedge News, February 9, 2023
GICS 2023 Monitoring ctDNA After Colorectal Cancer Surgery
Medscape Medical News, February 2, 2023
GICS 2023 Palliative Radiotherapy Reduces End-Stage Liver Cancer Pain
MDedge News, January 26, 2023

GICS 2023 Regorafenib: New Option for Advanced Gastroesophageal Cancer?
Medscape Medical News, January 24, 2023
GICS 2023 SUNLIGHT: New Standard of Care in Refractory Metastatic CRC
Medscape Medical News, January 23, 2023
GICS 2023 Adding SBRT to Sorafenib Boosts Survival in Liver Cancer
Medscape Medical News, January 23, 2023
GICS 2023 New 'Reference Regimen' in Metastatic Pancreatic Cancer?
Medscape Medical News, January 23, 2023
GICS 2023 Longest Overall Survival Ever Seen in Advanced Gastric Cancer
Medscape Medical News, January 20, 2023

Medscape Oncology© WebMD, LLC

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Perspectives

2023 ASCO GI Symposium: New, Measured Optimism
Mark A. Lewis, MD

Popular News from GICS 2022

New Drug Combo Potentially Practice Changing in Advanced HCC Atezolizumab plus bevacizumab was superior to sorafenib for maintaining quality of life in patients with unresectable hepatocellular carcinoma (HCC).
Medscape Medical News, Jan 27, 2020
Dual Immunotherapy Promising New Option for Liver Cancer The combination of durvalumab plus the experimental drug tremelimumab significantly improved overall survival as compared to sorafenib.
Medscape Medical News, Jan 24, 2022
Three Trials From ASCO GI Renew Hope KRYSTAL-1, TOPAZ, and HIMALAYA are more than just catchy trial acronyms, says Dr Mark Lewis.
Medscape Medical News, Mar 08, 2022

Previous Coverage